Recently, six PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib, fluzoparib, and pamiparib) were approved for use in the treatment of ovarian, breast, and pancreatic cancers. This evidence concerns the gene PARP1 and pancreatic neoplasm.